ECRONICON OPEN ACCESS

EC NEUROLOGY
Review Article

The Promise of Nanosensors in the Early Detection of Parkinson's Disease Biomarkers

Huma Ikram*

Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Karachi, Pakistan

***Corresponding Author:** Huma Ikram, Associate Professor, Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Karachi, Pakistan.

Received: November 21, 2025; **Published:** December 03, 2025

Abstract

The promise of nanosensors for the early detection of Parkinson's disease biomarkers lies in their unparalleled sensitivity and miniaturization, which allow for the identification of pathological signs at ultralow concentrations. These advanced tools show immense potential in analyzing key biofluids, including blood and cerebrospinal fluid for direct biomarkers, as well as non-invasive sources like saliva and tears, which offer a convenient window into neurological health. Furthermore, the development of specialized nanoprobes enables the *in vivo* imaging of pathological protein aggregates within the brain, providing a real-time view of disease progression. The power of these technologies is greatly amplified by integration with artificial intelligence, which can decipher complex biomarker patterns to predict disease onset and stratify patients. However, the path to clinical adoption faces significant challenges, including ensuring biocompatibility, achieving manufacturing scalability, navigating regulatory pathways, and conclusively demonstrating clinical utility. Future progress depends on interdisciplinary efforts to create multiplexed, point-of-care, and even theranostic platforms that combine diagnosis with treatment. Ultimately, by overcoming these translational hurdles, nanosensor technology holds the potential to revolutionize Parkinson's disease management by enabling pre-symptomatic detection and personalized intervention.

Keywords: *Nanosensors; Parkinson's Disease; Early Detection; Biomarkers; Neurodegenerative Diseases; Diagnostics; Alpha-Synuclein; Liquid Biopsy*



Graphical Abstract

Introduction

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons and the accumulation of misfolded proteins, such as alpha-synuclein. A significant challenge in managing PD is the lack of definitive diagnostic tools for its early, pre-symptomatic stages, often leading to diagnosis only after substantial and irreversible neuronal damage has occurred. Current methods are primarily clinical and lack the sensitivity for early detection, while confirmatory biomarkers have been elusive. The emerging field of nanotechnology offers a transformative solution to this diagnostic impasse. Nanosensors, with their exceptional sensitivity, miniaturization, and capacity for multiplexing, present a powerful platform for detecting PD-specific biomarkers in accessible biofluids like blood, saliva, and cerebrospinal fluid. This review explores the immense promise of nanosensor technology in revolutionizing the early diagnosis of Parkinson's disease, thereby opening new avenues for timely intervention and improved patient outcomes.

Need for early Parkinson's diagnosis

The current diagnostic paradigm for Parkinson's disease is fundamentally reactive, relying on the clinical identification of cardinal motor symptoms such as tremor, bradykinesia, and rigidity. These hallmark signs only become apparent after a prolonged prodromal phase characterized by extensive and irreversible neurodegeneration in the substantia nigra pars compacta [1]. By the time a clinical diagnosis is confirmed, an estimated 50-70% of dopaminergic neurons have been lost, representing a pathological point of no return. This significant delay creates a critical missed therapeutic window, as neuroprotective strategies are likely most effective in the earliest stages before widespread neuronal death occurs. The entire clinical framework is thus built upon detecting the consequences of the disease rather than its initial causes. Therefore, a paradigm shift from symptomatic to pre-symptomatic diagnosis is an urgent clinical and scientific necessity. This revolution in approach is the foundational step required to meaningfully alter the disease's devastating trajectory.

The absence of early biomarkers critically impedes the development of disease-modifying therapies and creates a substantial socio-economic burden. Clinical trials for neuroprotective agents have repeatedly failed, in part because they enroll participants at moderate disease stages where the potential for neuronal rescue is minimal [2]. Parkinson disease is a heterogeneous disease with rapidly and slowly progressive forms. Treatment involves pharmacologic approaches (typically with levodopa preparations prescribed with or without other medications) and nonpharmacologic approaches (such as exercise and physical, occupational, and speech therapies). Furthermore, prodromal non-motor symptoms like REM sleep behavior disorder and hyposmia are often misattributed, leading to patient distress and unnecessary healthcare utilization. The global economic burden of Parkinson's disease is substantial and rises dramatically with increasing disease severity and disability [3]. Investing in early diagnostic technologies is therefore not only a clinical imperative but also a socio-economic one with potential for substantial long-term savings. The pursuit of early biomarkers is thus inextricably linked to the success of future therapeutic and health-economic strategies.

Beyond the neurological system, the consequences of late diagnosis profoundly impact patient autonomy, quality of life, and psychological well-being. An early diagnosis empowers individuals with the agency to make informed personal, financial, and lifestyle decisions long before significant disability occurs. It also facilitates the timely management of both motor and non-motor symptoms, which can significantly improve daily functioning from the outset of the disease journey [4]. The psychological burden of a protracted diagnostic odyssey, characterized by uncertainty and misdiagnosis, places an immense and often overlooked strain on patients and their families. The promise of pre-symptomatic detection lies in validating the patient experience and providing a clear framework for future planning. The development of sensitive tools, particularly nanosensors, is crucial for creating a more humane and proactive framework for managing Parkinson's disease [5]. Ultimately, achieving early diagnosis is a moral imperative that would restore a sense of control and hope to those facing the prospect of this neurodegenerative condition.



Figure 1: *Nanosensor-based diagnostic workflow.*

Key pathological hallmarks of PD

The defining neuropathological feature of Parkinson's disease is the abnormal accumulation of the presynaptic protein alpha-synuclein (α-syn). This protein misfolds and aggregates into intraneuronal inclusions known as Lewy bodies and Lewy neurites, which are the definitive hallmark of the disease at post-mortem examination [6]. The prion-like hypothesis suggests that pathological α-syn can template its own misfolding and spread in a predictable pattern through neural networks, correlating with disease progression. These aggregates are thought to disrupt crucial cellular functions, including synaptic transmission and axonal transport, leading to neuronal dysfunction. The presence of Lewy pathology in specific regions, such as the olfactory bulb and dorsal motor nucleus of the vagus, may explain the early non-motor symptoms that precede motor signs by years. Understanding the molecular mechanisms of α-syn aggregation is therefore paramount for developing targeted diagnostics and therapies. This protein-centric pathology provides a primary molecular target for novel detection strategies, including nanosensor platforms.

Concurrent with protein aggregation, mitochondrial dysfunction and impaired proteostasis create a toxic intracellular environment that drives neurodegeneration. A significant loss of mitochondrial complex I activity has been consistently documented in the substantia nigra of Parkinson's patients, leading to bioenergetic failure and increased oxidative stress [7]. This oxidative damage further exacerbates protein misfolding and damages lipids and DNA, creating a vicious cycle of cellular injury. Furthermore, both the ubiquitin-proteasome system and the autophagy-lysosomal pathway, the cell's primary protein clearance mechanisms, are often impaired in Parkinson's pathology. This failure in cellular "housekeeping" allows for the accumulation of damaged proteins and organelles, accelerating neuronal death. The vulnerability of dopaminergic neurons is partly attributed to their high metabolic demands and complex axonal arbors, making them particularly susceptible to these forms of cellular stress. These interconnected pathways of mitochondrial failure and proteostatic collapse represent critical secondary targets for biomarker development.

Widespread neuroinflammation and specific genetic factors are now recognized as integral contributors to the disease's pathogenesis and progression. Chronic activation of microglia, the brain's resident immune cells, is a persistent feature observed in Parkinson's disease patients, leading to the sustained release of pro-inflammatory cytokines [8]. This neuroinflammatory response is not merely a consequence of neurodegeneration but is believed to actively contribute to the propagation of pathology and neuronal loss. Genetically, mutations in genes such as LRRK2 and GBA are significant risk factors that implicate specific pathways in disease etiology, including endolysosomal

function and immune response [9]. The complex interplay between genetic predisposition, protein aggregation, mitochondrial failure, and neuroinflammation creates a self-reinforcing pathological loop. This multifaceted nature underscores that Parkinson's is not a single-mechanism disorder but a complex syndrome with converging pathological streams. A comprehensive biomarker strategy must therefore account for this heterogeneity to achieve accurate early detection and patient stratification [10].

Parkinson's biomarker landscape

The search for reliable Parkinson's disease biomarkers has evolved into a dynamic field, encompassing molecular, imaging, and genetic modalities to capture the disease's complexity. Molecular biomarkers in cerebrospinal fluid (CSF) and blood are at the forefront, with pathological forms of alpha-synuclein (α-syn) being the most sought-after targets. The real-time quaking-induced conversion (RT-QuIC) assay, which detects seeding-competent α-syn in CSF, has demonstrated exceptionally high diagnostic accuracy, heralding a new era in molecular diagnosis [11]. Beyond α-syn, neurofilament light chain (NfL) has emerged as a robust marker for general axonal damage, helping to distinguish Parkinson's from atypical parkinsonisms. Additionally, biomarkers reflecting underlying pathophysiology, such as DJ-1 for oxidative stress and various inflammatory cytokines, are being actively investigated. The shift towards minimally invasive liquid biopsies is a major trend, driving research to validate these markers in blood plasma and serum. This comprehensive molecular approach aims to provide a multifaceted view of the disease's biological state.

Imaging and genetic biomarkers provide complementary tools for diagnosis, stratification, and tracking disease progression. Dopamine transporter (DAT) SPECT imaging remains a widely used technique to visualize the presynaptic dopaminergic deficit, confirming the involvement of the nigrostriatal pathway [12]. However, its limitation lies in detecting changes only after significant neuronal loss has already occurred. Emerging imaging techniques, such as quantitative MRI and tau-PET, are being explored to assess nigral degeneration and co-pathologies, respectively. In the genetic realm, mutations in genes like LRRK2 and GBA are not only significant risk factors but also enable patient stratification for targeted therapies, paving the way for personalized medicine [13]. The identification of specific genetic subtypes allows for the development of tailored biomarker panels that can monitor treatment response in clinical trials. Integrating these diverse data types is crucial for constructing a complete picture of an individual's disease.

The future of Parkinson's biomarkers lies in the convergence of novel biological sources and advanced analytical technologies. The analysis of extracellular vesicles, particularly those of neuronal origin, is a highly promising avenue as they can cross the blood-brain barrier and carry a "molecular signature" from the brain into the periphery [14]. Furthermore, metabolomic and lipidomic profiling are uncovering distinct biochemical shifts in biofluids, providing functional insights into the underlying mitochondrial and oxidative stress pathways. The field is also exploring the potential of digital biomarkers derived from wearable sensors to quantify subtle motor and non-motor changes continuously and objectively. A major challenge remains the biological heterogeneity of PD itself, suggesting that a single biomarker will be insufficient for all cases [15]. The ultimate goal is to develop integrated panels that combine molecular, imaging, genetic, and digital biomarkers to achieve the sensitivity and specificity required for a definitive early diagnosis. This rich and evolving biomarker landscape forms the essential foundation upon which advanced detection technologies, particularly nanosensors, can be deployed to revolutionize clinical practice.

Nanosensors: Principles and enhanced sensitivity

Nanosensors are analytical devices that transduce a biological binding event into a quantifiable physical signal through components engineered at the nanoscale (1-100 nm). Their fundamental operating principle relies on the specific recognition of a target analyte by a biorecognition element immobilized on the nanomaterial's surface, such as an antibody, aptamer, or peptide. This specific binding event induces a measurable change in a physical property of the nanomaterial, which can be optical, electrical, or mechanical in nature. The exceptionally high surface-to-volume ratio of nanomaterials is a cornerstone of their enhanced sensitivity, allowing for a vastly greater

density of receptor molecules compared to macroscale sensors. This maximized surface area significantly increases the probability of capturing low-abundance target molecules, which is crucial for detecting faint pathological signals in complex biofluids like blood or cerebrospinal fluid. Furthermore, the nanoscale dimensions of these transducers are commensurate with the biomarkers themselves, leading to highly efficient signal generation and transduction upon binding. These foundational principles collectively enable nanosensors to achieve detection limits that are often orders of magnitude lower than those of conventional assays like ELISA [16].

The extraordinary sensitivity of nanosensors is largely derived from the unique quantum and surface-dominated phenomena that emerge at the nanoscale. Noble metal nanoparticles, such as gold and silver, exhibit a phenomenon known as localized surface plasmon resonance (LSPR), where incident light induces collective oscillations of conduction electrons, producing intense, tunable light absorption and scattering. The LSPR signal is exquisitely sensitive to changes in the local refractive index, such as those caused by the binding of a target biomarker, enabling highly sensitive, label-free detection with simple spectrophotometers [17]. Quantum dots, which are semiconductor nanocrystals, offer superior optical properties like high quantum yield, photostability, and size-tunable emission wavelengths, making them brilliant fluorescent labels for multiplexed assays. Carbon-based nanomaterials like graphene and carbon nanotubes possess extraordinary electrical conductivity and high carrier mobility, making them excellent transducers for electrochemical and field-effect transistor (FET) biosensors where binding events cause measurable changes in current. The ability to exploit these quantum and surface phenomena is what fundamentally differentiates nanosensors from traditional analytical platforms. This allows for the detection of minute changes in biomarker concentration, pushing detection limits to clinically relevant ranges necessary for pre-symptomatic Parkinson's diagnosis [18].



Figure 2: *Development of a PD nanosensor.*

The functionalization and design of the nanosensor interface are critical for translating their inherent physical advantages into specific and reliable diagnostic tools. The surface of nanomaterials can be precisely engineered and conjugated with high-affinity biorecognition elements that act as molecular hooks for specific PD biomarkers like oligomeric alpha-synuclein. Aptamers, which are single-stranded DNA or RNA oligonucleotides selected *in vitro*, are particularly advantageous due to their high specificity, stability, and ability to distinguish between subtly different protein conformations [19]. A critical aspect of design involves minimizing non-specific adsorption from complex matrices like blood plasma, often achieved using passivation layers like polyethylene glycol (PEG) to create a "non-fouling" background.

Furthermore, nanosensors can be designed for multiplexing, allowing for the simultaneous detection of a panel of PD biomarkers from a single, small-volume sample, which is essential for improving diagnostic accuracy given the disease's heterogeneity. Advanced systems also integrate signal amplification strategies, such as the use of enzymatic labels or plasmonic coupling between nanoparticles, to push detection limits even further into the sub-femtomolar range [20,21]. This meticulous bio-interface engineering, combined with the intrinsic sensitivity of the nanomaterials, creates a powerful and versatile platform capable of addressing the stringent demands of early and accurate Parkinson's disease diagnosis.

Detecting alpha-synuclein with nanosensors

The pathological aggregation of alpha-synuclein (α-syn) is a central event in Parkinson's disease, making its detection a primary target for early diagnosis. However, accurately measuring α-syn in biofluids is challenging due to its low concentration, structural heterogeneity, and the presence of a complex protein matrix. Nanosensors are uniquely positioned to overcome these hurdles by offering platforms with the requisite sensitivity and specificity to distinguish between monomeric, oligomeric, and fibrillar forms of the protein. The oligomeric species are particularly recognized for their neurotoxicity and are considered a more relevant biomarker than the total α-syn load. By functionalizing nanomaterial surfaces with conformation-specific antibodies or aptamers, nanosensors can selectively capture these pathogenic oligomers. This targeted approach is crucial because conventional assays often fail to differentiate the toxic oligomers from the more abundant but less harmful monomers or large aggregates. The application of nanosensors for α-syn detection thus represents a significant leap forward in molecular diagnosis, moving beyond mere presence/absence to assessing pathological activity [22].

Electrochemical nanosensor platforms have demonstrated remarkable success in detecting α-syn with high sensitivity, often in complex samples. These sensors typically utilize electrodes modified with nanomaterials like graphene, carbon nanotubes, or gold nanoparticles to enhance the electrochemical signal upon α-syn binding. A common strategy involves immobilizing an anti-α-syn antibody on the electrode surface, which captures the target protein, leading to a measurable change in electrical properties like impedance or current. For instance, a graphene-based field-effect transistor (FET) biosensor can detect picomolar concentrations of α-syn oligomers by monitoring the conductance change induced by the protein's binding event. The signal can be further amplified by using enzymatic labels or redox-active reporters that generate a strong electrochemical readout. This high sensitivity allows for the direct analysis of clinically relevant samples, such as diluted blood plasma or cerebrospinal fluid, without extensive pre-processing. The portability and potential for miniaturization of electrochemical systems also point toward future point-of-care diagnostic devices for Parkinson's disease [23].

Optical nanosensors provide a powerful alternative, leveraging the distinctive properties of nanomaterials to create highly sensitive and multiplexable detection systems. Localized surface plasmon resonance (LSPR) sensors using gold nanoparticles or nanorods are highly effective, as the binding of α-syn causes a measurable shift in the resonance wavelength due to a change in the local refractive index. Fluorescence-based sensors often employ Förster Resonance Energy Transfer (FRET), where a quantum dot or dye-labeled antibody donor transfers energy to an acceptor upon α-syn binding, resulting in a quantifiable change in fluorescence emission. A significant advantage of optical nanosensors is their ability to be designed for multiplexing, allowing simultaneous detection of different α-syn species or other PD-related biomarkers like Aβ and tau on a single platform. Surface-Enhanced Raman Spectroscopy (SERS)-based sensors offer another avenue, providing a unique molecular fingerprint for α-syn with enormous signal enhancement from metallic nanostructures. These optical methods are generally label-free or require minimal labeling, facilitating rapid and direct analysis. The continuous development of these diverse optical nanosensing strategies is crucial for creating a robust and verifiable diagnostic test for the early stages of Parkinson's pathology [24].



Figure 3: *Pathways to personalized PD diagnosis.*

Beyond synuclein: Other key biomarkers

While alpha-synuclein is the quintessential Parkinson's disease biomarker, the multifaceted nature of the pathology necessitates a multi-analyte approach for a comprehensive diagnosis. Neuroinflammation is a key driver of disease progression, making cytokines and other inflammatory mediators promising targets for detection. Elevated levels of pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6 in the blood and CSF of PD patients provide a quantifiable measure of this ongoing inflammatory process [25]. Furthermore, neurofilament light chain (NfL) has emerged as a robust and reliable marker for active axonal damage and neurodegeneration. Its concentration in blood serum correlates with disease severity and progression, and it is particularly useful in differentiating Parkinson's from atypical parkinsonian disorders like Multiple System Atrophy. Detecting these inflammatory and neuronal injury markers alongside α-syn would provide a more holistic view of the disease activity. Nanosensors capable of multiplexed analysis are ideally suited to capture this complex biomarker signature from a single, small-volume sample.

Beyond markers of cell damage, indicators of fundamental cellular dysfunction offer another rich vein for biomarker discovery. Mitochondrial impairment, a core pathological feature, leaves a traceable metabolic signature that can be detected in biofluids. Key metabolites in the Krebs cycle, such as reduced levels of citrate and succinate, have been identified as potential indicators of the bioenergetic deficit in PD [26]. Additionally, the ratio of reduced to oxidized glutathione is a sensitive measure of systemic oxidative stress, reflecting the brain's antioxidant capacity. Lysosomal dysfunction, often linked to GBA mutations, can be assessed by measuring the activity of specific enzymes like glucocerebrosidase or by profiling specific sphingolipids in plasma. These metabolic and enzymatic biomarkers provide a dynamic snapshot of the underlying cellular pathologies driving neurodegeneration. Their detection requires highly sensitive platforms, as they are often present at low concentrations, making nanosensors a perfect technological match for their quantification.

The genetic landscape of Parkinson's disease also contributes biomarkers that are invaluable for risk assessment and patient stratification. While not diagnostic on their own, mutations in genes like LRRK2 and GBA represent the most significant known risk factors for developing the disease [27]. The identification of these mutations, especially in prodromal individuals, can define a high-risk population that would benefit immensely from intensive monitoring and early intervention. Beyond DNA-based risk, RNA biomarkers, such as specific microRNA (miRNA) profiles in blood or extracellular vesicles, are emerging as indicators of disease state and progression [28]. These circulating miRNAs can regulate gene expression and are often dysregulated in neurodegeneration. The integration of genetic, transcriptomic, and proteomic data is the future of PD diagnostics, creating a multi-layered, personalized biomarker profile. Nanosensor arrays, with their capacity for high-throughput and parallel detection, are poised to be the enabling technology that makes this integrated diagnostic approach a clinical reality.

Nanosensors in blood and cerebrospinal fluid

The detection of Parkinson's disease biomarkers in blood and cerebrospinal fluid (CSF) represents a critical frontier in early diagnosis, as these biofluids contain key pathological indicators such as alpha-synuclein aggregates and dopamine metabolites. Nanosensors, with their exceptional sensitivity and miniaturization, are ideally suited for analyzing these complex matrices, enabling the identification of biomarkers at ultralow concentrations that traditional methods often miss. For instance, CSF is particularly valuable due to its direct contact with the central nervous system, providing a rich source of disease-specific proteins and neurotransmitters. Recent studies have demonstrated that electrochemical nanosensors can detect oligomeric alpha-synuclein in CSF with remarkable precision, offering a non-invasive approach to monitoring disease progression [29]. Similarly, blood-based nanosensors leverage plasmonic and fluorescent techniques to identify biomarkers like DJ-1 and LRRK2, which are implicated in Parkinson's pathology [30]. The integration of nanomaterials such as gold nanoparticles and carbon nanotubes enhances signal amplification, reducing false positives and improving reliability in clinical samples. Ultimately, the application of nanosensors in these biofluids holds promise for developing liquid biopsies that could revolutionize early Parkinson's diagnosis.

Advancements in nanosensor design have focused on improving selectivity and multiplexing capabilities for simultaneous detection of multiple Parkinson's biomarkers in blood and CSF. For example, graphene oxide-based nanosensors functionalized with specific antibodies can selectively bind to alpha-synuclein fibrils in CSF, producing quantifiable optical or electrical signals that correlate with disease stages [31]. In blood, similar platforms utilize magnetic nanoparticles to isolate and detect exosomal biomarkers, allowing for high-throughput screening without extensive sample preparation [32]. These systems often incorporate microfluidic components to handle small sample volumes, making them suitable for point-of-care testing in resource-limited settings. Recent research has also explored the use of aptamer-conjugated nanosensors that target catecholamines in CSF, providing real-time monitoring of dopamine fluctuations associated with Parkinson's motor symptoms [33]. Moreover, the development of label-free nanosensors reduces processing time and cost, facilitating their translation into routine clinical practice. As a result, these innovations are paving the way for more personalized and accessible diagnostic tools.



Figure 4: *Navigating PD biomarkers detection: invasive vs non-invasive.*

Despite the progress, several challenges remain in the widespread adoption of nanosensors for Parkinson's biomarker detection in blood and CSF, including issues related to biocompatibility, standardization, and regulatory approval. Variability in biomarker levels across individuals and the need for robust calibration in diverse populations complicate the interpretation of nanosensor data, necessitating large-scale validation studies [34]. Future directions involve integrating artificial intelligence with nanosensor arrays to enhance data analysis and predict disease onset with higher accuracy, as demonstrated in recent pilot studies using machine learning algorithms. Additionally, efforts are underway to develop wearable nanosensors that continuously monitor biomarker fluctuations in blood, providing dynamic insights into disease progression and treatment efficacy [30]. Collaborative initiatives between academia and industry are crucial for addressing manufacturing scalability and ensuring that these technologies meet clinical standards. Ultimately, overcoming these hurdles will unlock the full potential of nanosensors in transforming Parkinson's disease management through early and precise intervention.

Non-invasive detection of Parkinson's disease: Saliva and tears

The pursuit of non-invasive diagnostic routes for Parkinson's disease has intensified, with saliva and tears emerging as highly accessible biofluids rich in disease-specific biomarkers. Saliva, in particular, contains various constituents, including proteins, metabolites, and nucleic acids, that can reflect pathological changes occurring in the brain, offering a promising medium for early screening. Research has confirmed the presence of pathological alpha-synuclein oligomers in the saliva of Parkinson's patients, providing a direct molecular target for nanosensor technology [34]. Electrochemical nanosensors functionalized with specific antibodies can capture these oligomers, translating their presence into a measurable electrical signal with high sensitivity, thus bypassing the need for complex laboratory analysis. Similarly, nanosensors designed to detect salivary DJ-1 protein, a potential biomarker for oxidative stress in Parkinson's, have shown significant correlations with clinical scores of disease severity [35]. The development of these platforms is further enhanced by using nanomaterials like graphene and quantum dots, which improve the stability and signal-to-noise ratio in the complex salivary matrix. Consequently, salivary nanosensors present a straightforward and patient-compliant strategy for the decentralized monitoring of Parkinson's disease.

Tear fluid represents another compelling, yet under-explored, non-invasive source of biomarkers, as its production is innervated by the same neuropathways affected in Parkinson's disease. The composition of tears, including proteins like lacritin and lysozyme, can be altered by neurodegenerative processes, providing a unique window into neurological health. Recent proteomic studies have identified distinct protein signatures in the tears of Parkinson's patients, establishing a foundation for targeted nanosensor development [36]. Optical nanosensors, particularly those based on surface-enhanced Raman spectroscopy (SERS), have been engineered to detect these subtle protein changes with exceptional precision, requiring only minute sample volumes collected via simple capillary tubes. This approach allows for the multiplexed detection of several biomarkers simultaneously, creating a more robust diagnostic profile than any single analyte could provide. Furthermore, the integration of these nanosensors into potential smart contact lens devices could enable continuous, real-time monitoring of disease biomarkers, representing a paradigm shift in patient management [37,38]. The exploration of tear fluid thus marks a significant advancement toward truly non-intrusive and continuous neurological diagnostics.

Despite the considerable promise of saliva and tear-based nanosensing, several technical and practical challenges must be addressed before these technologies can be translated into routine clinical practice. The primary hurdle is the variable composition of these biofluids, which can be influenced by factors like diet, hydration, and circadian rhythms, potentially leading to inconsistent readings and requiring sophisticated normalization algorithms [39]. Future research must focus on large-scale, longitudinal studies to validate the specificity and sensitivity of these nanosensors against established diagnostic standards and to confirm their ability to detect pre-motor stages of Parkinson's. Innovations in sample collection and preparation are also critical, as developing standardized, user-friendly kits will be essential for widespread adoption outside specialized clinics. Concurrently, the issue of regulatory approval and manufacturing scalability for these complex nanodevices remains a significant barrier that requires collaborative efforts between engineers, clinicians, and industry

partners. By systematically overcoming these obstacles, nanosensors for saliva and tears have the potential to democratize Parkinson's disease diagnosis, making early detection accessible in primary care settings and at home.

In vivo imaging with nanoprobes

The development of *in vivo* imaging nanoprobes offers a transformative approach for visualizing the pathological hallmarks of Parkinson's disease directly within the living brain, moving beyond post-mortem confirmation. These engineered nanoscale agents are designed to cross the blood-brain barrier and selectively bind to targets such as alpha-synuclein fibrils or iron-rich microglia, providing a real-time window into disease progression. Magnetic resonance imaging (MRI) has been significantly enhanced by nanoprobes utilizing superparamagnetic iron oxide nanoparticles, which create hypointense signals in regions of neuroinflammation, a key contributor to dopaminergic neuron loss [40]. Similarly, for nuclear imaging, radiolabeled nanoprobes targeting alpha-synuclein aggregates are being developed for positron emission tomography (PET), potentially enabling the specific detection of Lewy body pathology years before overt symptoms appear [41]. The high surface-area-to-volume ratio of nanoparticles allows for the conjugation of multiple targeting ligands and contrast agents, dramatically improving signal strength and specificity compared to conventional molecular probes. This multi-functional design facilitates the use of multimodal imaging, where a single nanoprobe can be detected by both MRI and fluorescence imaging, correlating anatomical changes with molecular events. Therefore, *in vivo* nanoprobes represent a powerful tool for not only diagnosing Parkinson's but also for monitoring the efficacy of novel disease-modifying therapies in clinical trials.

A significant frontier in this field is the creation of "smart" activatable nanoprobes that remain silent until they encounter their specific pathological target, thereby reducing background noise and increasing diagnostic accuracy. For instance, near-infrared fluorescence (NIRF) nanoprobes have been engineered to emit a strong signal only upon cleavage by enzymes that are upregulated in the Parkinsonian brain, such as caspase-3 involved in apoptotic pathways [42]. Quantum dots capped with a quencher-linked peptide specific for alpha-synuclein represent another innovative design, where fluorescence is restored only upon binding to the misfolded protein aggregates [43]. This target-activated switching is crucial for distinguishing pathological protein clusters from their benign, monomeric forms, a challenge that has plagued previous imaging efforts. Furthermore, the application of these nanoprobes in conjunction with intravital microscopy allows researchers to observe the dynamics of neurodegeneration and protein spread in real-time within animal models. As these technologies mature, the focus is shifting toward designing nanoprobes with enhanced biocompatibility and rapid clearance profiles to minimize long-term tissue retention. The evolution of these intelligent, responsive agents is paving the way for a new era of precision neurology, where disease-specific molecular events can be visualized with unprecedented clarity.

Despite the remarkable potential of imaging nanoprobes, several formidable challenges must be overcome before their routine translation into human clinical practice. A primary concern is the long-term biodistribution and potential toxicity of these non-biodegradable nanomaterials, necessitating comprehensive toxicological studies and the development of more biocompatible, self-assembling platforms from peptides or lipids [44]. The heterogeneity of Parkinson's pathology itself presents another hurdle, as the distribution of alpha-synuclein aggregates can vary significantly between patients, requiring nanoprobes with broad specificity to capture the full spectrum of the disease [45]. Future research directions are increasingly focused on theranostics, merging diagnostic capabilities with therapeutic functions, such as nanoprobes that can release a neuroprotective drug upon target binding [40]. The integration of artificial intelligence to analyze the complex, multi-parametric data generated by these imaging studies will also be critical for distinguishing Parkinson's from other parkinsonian syndromes and for predicting individual disease trajectories [41]. Collaborative efforts between nanomaterial scientists, neurologists, and regulatory bodies are essential to establish standardized safety and efficacy protocols. Ultimately, successfully navigating these challenges will unlock the potential of *in vivo* nanoprobes to revolutionize our understanding and clinical management of Parkinson's disease from its earliest, pre-symptomatic stages.

Role of AI in nanosensing

The integration of Artificial Intelligence (AI) with nanosensing platforms is revolutionizing the interpretation of complex biomarker data, moving beyond simple detection to predictive diagnostics for Parkinson's disease. AI algorithms, particularly machine learning (ML) models, are uniquely suited to deconvolute the multidimensional signals generated by nanosensor arrays, which often produce vast datasets from minimal sample volumes. For instance, a single electrochemical nanosensor test in blood or saliva can yield rich, non-linear data on alpha-synuclein species, catecholamines, and inflammatory markers simultaneously. Deep learning networks can be trained to identify subtle, hidden patterns within this data that are imperceptible to human analysis, correlating specific biomarker fingerprints with pre-motor stages of Parkinson's with high accuracy [46]. This capability allows for the stratification of patients into distinct prognostic subgroups, facilitating a more personalized approach to disease management. Furthermore, AI-driven analysis significantly reduces the time from data acquisition to a clinically actionable result, accelerating the diagnostic workflow. Consequently, the synergy of AI and nanosensing is creating a new paradigm where biosensors do not just report data, but provide intelligent, diagnostic insights.

A critical application of AI lies in the design and optimization of the nanosensors themselves, a process that is being transformed through computational modeling and generative algorithms. The performance of a nanosensor is heavily dependent on its physical properties, such as the size, shape, and surface chemistry of the nanoparticle core and its biorecognition elements. AI models can now predict the binding affinity of thousands of potential aptamer sequences for a target like pathological alpha-synuclein, drastically shortening the development cycle for new detection probes [47]. In material science, generative adversarial networks (GANs) are being used to propose novel nanocomposite structures with ideal electrical or optical properties for specific sensing applications in cerebrospinal fluid [48]. This AI-driven design process enables the creation of highly specific nanosensors that can discriminate between oligomeric and fibrillar forms of alpha-synuclein, a distinction crucial for accurate diagnosis. By simulating countless design iterations in silico, AI minimizes costly and time-consuming experimental trial-and-error. This intelligent design pipeline is therefore essential for developing the next generation of ultra-specific, multiplexed nanosensing platforms.



Figure 5: *AI-nanosensor synergy for PD diagnosis.*

Despite its promise, the widespread clinical deployment of AI-enhanced nanosensing faces significant challenges related to data quality, model interpretability, and ethical considerations. The performance of any ML model is entirely dependent on the quality and size of the training dataset, which requires large, well-annotated, and diverse biosample libraries that are currently limited for pre-symptomatic Parkinson's [49]. The "black box" nature of some complex AI models can also be a barrier to clinical adoption, as physicians require understandable rationale for a diagnosis; explainable AI (XAI) techniques are now being developed to make these decisions more transparent [50]. Future directions point toward the creation of federated learning systems, where AI models can be trained on data from multiple institutions without the data itself ever leaving the host hospital, thus preserving patient privacy [46]. The ultimate goal is a closed-loop system where continuous data from wearable or implantable nanosensors is analyzed in real-time by AI, providing dynamic risk assessments and early warnings. Navigating these challenges responsibly is key to unlocking the full potential of AI as an indispensable partner in nanosensing for transforming Parkinson's disease diagnostics.

Challenges in clinical translation

The transition of nanosensor technology from sophisticated laboratory prototypes to clinically approved diagnostic tools for Parkinson's disease is fraught with significant and multifaceted challenges. A primary hurdle is ensuring the long-term biocompatibility and safety of these nanoscale materials within the human body, as their potential for accumulation and unforeseen immunogenic reactions remains a critical concern for regulatory agencies like the FDA and EMA. The complex and heterogeneous nature of biological matrices, such as blood and saliva, introduces substantial variability, where proteins and other biomolecules can non-specifically adsorb to the sensor surface in a phenomenon known as biofouling, severely compromising analytical accuracy and reliability [51]. Furthermore, the disease's own pathological complexity, with its wide spectrum of alpha-synuclein strains and concurrent biomarkers, demands that nanosensors achieve an exceptionally high level of specificity to avoid cross-reactivity and false positives [52]. Reproducible manufacturing of nanosensors at a commercial scale presents another formidable obstacle, as maintaining precise control over nanoparticle size, shape, and surface functionalization across large batches is technically demanding and costly. The regulatory pathway itself is also ill-defined for such novel diagnostic entities, lacking specific guidelines for the validation of nanomaterial-based *in vitro* or *in vivo* devices, which creates uncertainty for developers [53]. Overcoming these intertwined biological, manufacturing, and regulatory barriers is therefore the first and most critical step toward any successful clinical application.

Beyond initial safety and production issues, the clinical validation of nanosensors requires demonstrating not just analytical performance but also tangible clinical utility in real-world settings. This necessitates large-scale, longitudinal multi-center trials that follow patients from pre-symptomatic stages to confirmed diagnosis, a process that is incredibly time-consuming and expensive [54]. A significant challenge in these trials is the current lack of a definitive gold standard for antemortem Parkinson's diagnosis, making it difficult to conclusively validate the sensitivity and specificity of a new nanosensor against imperfect clinical criteria. The economic aspect cannot be overlooked, as the high development and production costs of nanosensors must be justified through demonstrable improvements in patient outcomes or reductions in overall healthcare spending, requiring thorough health-economic analyses [55]. There is also a pressing need to standardize pre-analytical procedures, such as sample collection, storage, and processing, to ensure that nanosensor readings are consistent and comparable across different clinical sites and populations. Additionally, the successful integration of these technologies into existing clinical workflows demands robust, user-friendly platforms that can be operated reliably by healthcare staff without specialized nanotechnology training. Proving that nanosensors provide a clear advantage over existing diagnostic methods in a cost-effective manner is arguably the most significant barrier to their widespread adoption in neurology clinics.

Looking forward, addressing these translational challenges requires a concerted, interdisciplinary effort that bridges the gap between engineering laboratories, clinical neurology, and industry partners. Strategic research must prioritize the development of biodegradable or self-assembling nanosensors to alleviate long-term safety concerns, thereby simplifying the regulatory approval process [51]. To tackle the issue of clinical validation, international consortia should be established to create large, shared biobanks of well-characterized bio-

samples linked to comprehensive clinical data, which can be used to benchmark new nanosensing technologies [54]. Concurrently, close collaboration with regulatory bodies from the early stages of development is essential to shape future guidelines and create clear, adaptive pathways for the approval of complex nanomedicine products. From an engineering perspective, investing in automated, closed-system manufacturing platforms will be crucial for achieving the necessary reproducibility and scalability required for commercial success [53]. Finally, proactive engagement with clinicians, patients, and health economists is needed to design nanosensing solutions that are not only technologically advanced but also clinically desirable, accessible, and cost-effective [55]. By systematically addressing these translational roadblocks, the immense promise of nanosensors can finally be realized, paving the way for a new era in the early diagnosis and management of Parkinson's disease.

Future Perspectives and Conclusion

The future of Parkinson's disease diagnostics is poised for a transformative shift, driven by the convergence of nanosensing with artificial intelligence, advanced materials science, and point-of-care microfluidics. Next-generation research will focus on developing multiplexed platforms capable of simultaneously tracking a panel of biomarker fluctuations in real-time, providing a dynamic and holistic view of disease progression and therapeutic response. The integration of these nanosensors into wearable or implantable devices promises to enable continuous, at-home monitoring, moving diagnosis from episodic clinic visits to a seamless, integrated part of daily life. Furthermore, the paradigm is expanding from pure diagnostics to "theranostics," where a single nano-platform can not only detect a pathological signature but also locally release a neuroprotective agent, opening avenues for personalized and pre-emptive treatment strategies. Significant effort will also be directed toward creating fully integrated lab-on-a-chip systems that automate sample processing and analysis, making sophisticated biomarker detection accessible in primary care settings and underserved communities. However, realizing these future hinges on successfully navigating the remaining challenges of clinical validation, regulatory approval, and ensuring equitable access to these advanced technologies. In conclusion, while hurdles remain, the relentless advancement in nanosensor technology holds the unequivocal promise of revolutionizing Parkinson's disease care by enabling detection at the earliest, most tractable stages, ultimately altering the disease's trajectory for millions worldwide.

Bibliography

1. Munhoz RP., *et al*. "The clinical diagnosis of Parkinson's disease". *Arquivos de Neuro-Psiquiatria* 82.6 (2024): 1-10.

2. Tanaka M. "Parkinson's disease: Bridging gaps, building biomarkers, and reimagining clinical translation". *Cells* 14.15 (2025): 1161.

3. Armstrong MJ and Okun MS. "Diagnosis and treatment of Parkinson disease: a review". *Journal of the American Medical Association* 323.6 (2020): 548-560.

4. Gupta A., *et al*. "Quality of life and psychological problems in patients undergoing neurological rehabilitation". *Annals of Indian Academy of Neurology* 11.4 (2008): 225-230.

5. Willmen L., *et al*. "The economic burden of diagnostic uncertainty on rare disease patients". *BMC Health Services Research* 24.1 (2024): 1388.

6. Stefanis L. "α-synuclein in Parkinson's disease". *Cold Spring Harbor Perspectives in Medicine* 2.2 (2012): a009399.

7. Xie W., *et al*. "New insights into the role of mitochondrial dysfunction and protein aggregation in Parkinson's disease". *Biochimica et Biophysica Acta* 1802.11 (2010): 935-941.

8. Lind-Holm Mogensen F., *et al*. "Microglial dynamics and neuroinflammation in prodromal and early Parkinson's disease". *Journal of Neuroinflammation* 22.1 (2025): 136.

9. Arena G., *et al*. "Neurodegeneration and neuroinflammation in Parkinson's disease: a self-sustained loop". *Current Neurology and Neuroscience Reports* 22.8 (2022): 427-440.

10. Wardhan Y., *et al*. "Exploring the complex interplay between Parkinson's disease and BAG proteins". *Behavioural Brain Research* 469 (2024): 115054.

11. Sharma P and Dhamija RK. "The quest for Parkinson's disease biomarkers: traditional and emerging multi-omics approaches". *Molecular Biology Reports* 52.1 (2025): 831.

12. Akdemir ÜÖ., *et al*. "Dopamine transporter SPECT imaging in Parkinson's disease and parkinsonian disorders". *Turkish Journal of Medical Sciences* 51.2 (2021): 400-410.

13. Gujral J., *et al*. "PET, SPECT, and MRI imaging for evaluation of Parkinson's disease". *American Journal of Nuclear Medicine and Molecular Imaging* 14.6 (2024): 371-390.

14. Gualerzi A., *et al*. "Extracellular vesicles as biomarkers for Parkinson's disease: How far from clinical translation?". *International Journal of Molecular Sciences* 25.2 (2024): 1136.

15. Chen H., *et al*. "Metabolomic profiling uncovers diagnostic biomarkers and dysregulated pathways in Parkinson's disease". *Frontiers in Neurology* 16 (2025): 1608031.

16. Jiang P., *et al*. "Biosensors for early detection of Parkinson's disease: principles, applications, and future prospects". *Biosensors (Basel)* 15.5 (2025): 280.

17. Malekzad H., *et al*. "Noble metal nanoparticles in biosensors: recent studies and applications". *Nanotechnology Reviews* 6.3 (2017): 301-329.

18. Gao L., *et al*. "Nanotechnology for neurodegenerative diseases: recent progress in brain-targeted delivery, stimuli-responsive platforms, and organelle-specific therapeutics". *International Journal of Nanomedicine* 20 (2025): 11015-11044.

19. Yadav VK., *et al*. "Recent advances in nanotechnology for Parkinson's disease: diagnosis, treatment, and future perspectives". *Frontiers in Medicine (Lausanne)* 12 (2025): 1535682.

20. Shoukat CA., *et al*. "Plasmonic ELISA for biomarker detection: a review of mechanisms, functionalization strategies, and emerging modalities". *ACS Applied Bio Materials* 8.7 (2025): 5512-5531.

21. de la Rica R and Stevens MM. "Plasmonic ELISA for the ultrasensitive detection of disease biomarkers with the naked eye". *Nature Nanotechnology* 7.12 (2012): 821-824.

22. Silva IJSD., *et al*. "Alpha-synuclein aggregation in Parkinson's disease". *Advances in Protein Chemistry and Structural Biology* 146 (2025): 35-75.

23. Khatami SH., *et al*. "Electrochemical biosensors in early detection of Parkinson disease". *Clinica Chimica Acta* 565 (2025): 120001.

24. Mandala SHS., *et al*. "Enhanced plasmonic biosensor utilizing paired antibody and label-free Fe_3O_4 nanoparticles for highly sensitive and selective detection of Parkinson's α-synuclein in serum". *Biosensors (Basel)* 11.10 (2021): 402.

25. Hatano T., *et al*. "α-synuclein: A promising biomarker for Parkinson's disease and related disorders". *Journal of Movement Disorders* 17.2 (2024): 127-137.

26. Usha Kiran P., *et al*. "Mitochondrial dysfunction and oxidative stress in Parkinson's disease: mechanisms, biomarkers, and therapeutic strategies". *Tissue Barriers* (2025): 2537991.

27. Lunati A., *et al*. "The genetic landscape of Parkinson's disease". *Revue Neurologique (Paris)* 174.9 (2018): 628-643.

28. Billingsley KJ., *et al*. "Genetic risk factors in Parkinson's disease". *Cell and Tissue Research* 373.1 (2018): 9-20.

29. Dasari M and Medapati RV. "Cerebrospinal Fluid Biomarkers for Diagnosis of Parkinson's disease: A Systematic Review". *Cureus* 17.2 (2025): e79386.

30. Heineman A., *et al*. "Challenges and opportunities of early Parkinson's disease biomarkers: α-synuclein, leucine-rich repeat kinase 2 (LRRK2), DJ-1, and microRNA's". *Cureus* 17.9 (2025): e91510.

31. Yadav S., *et al*. "Nanobiosensors in neurodegenerative disease diagnosis: A promising pathway for early detection". *Digital Health* 11 (2025): 20552076251342457.

32. Jang YO., *et al*. "Transferrin-conjugated magnetic nanoparticles for the isolation of brain-derived blood exosomal MicroRNAs: A novel approach for Parkinson's disease diagnosis". *Analytica Chimica Acta* 1306 (2024): 342623.

33. Madhusudhan K., *et al*. "Early detection of Parkinson's disease via aptamer-CRISPR platform". *Neuroscience* 586 (2025): 163-195.

34. Liu N., *et al*. "Current trends in blood biomarkers detection and neuroimaging for Parkinson's disease". *Ageing Research Reviews* 104 (2025): 102658.

35. Adam H., *et al*. "Electro-sensing analysis for Parkinson's disease biomarker on dual-electrode surface: complemented by molecular docking". *Biotechnology and Applied Biochemistry* (2025).

36. Zetterberg H and Compta Y. "A tear fluid proteome of Parkinson's disease". *Parkinsonism and Related Disorders* 63 (2019): 1-2.

37. Gao F., *et al*. "SERS-based optical nanobiosensors for the detection of Alzheimer's disease". *Biosensors (Basel)* 13.9 (2023): 880.

38. Elsheikh S., *et al*. "Advancing brain research through surface-enhanced Raman spectroscopy (SERS): Current applications and future prospects". *Biosensors (Basel)* 14.1 (2024): 33.

39. Ali I., *et al*. "Nanotechnology in Parkinson's disease: overcoming drug delivery challenges and enhancing therapeutic outcomes". *Drug Delivery and Translational Research* (2025).

40. Belloli S., *et al*. "Translation imaging in Parkinson's disease: Focus on neuroinflammation". *Frontiers in Aging Neuroscience* 12 (2020): 152.

41. Tian GL., *et al*. "The development of a PET radiotracer for imaging alpha synuclein aggregates in Parkinson's disease". *RSC Medicinal Chemistry* (2025).

42. Gong T., *et al*. "Implication of bimodal magnetic resonance and fluorescence imaging probes in advanced healthcare: enhancing disease diagnosis and targeted therapy". *International Journal of Nanomedicine* 20 (2025): 9473-9503.

43. Li Q., *et al*. "Fluorescent probes for α-synuclein biomarkers: Innovations in early diagnosis and therapeutic monitoring of Parkinson's disease". *Clinica Chimica Acta* 579 (2025): 120612.

44. Grancharova T., *et al*. "Gold nanoparticles in Parkinson's disease therapy: a focus on plant-based green synthesis". *Cureus* 16.2 (2024): e54671.

45. Wüllner U., *et al*. "The heterogeneity of Parkinson's disease". *Journal of Neural Transmission (Vienna)* 130.6 (2023): 827-838.

46. Dennis AP and Strafella AP. "The role of AI and machine learning in the diagnosis of Parkinson's disease and atypical parkinsonisms". *Parkinsonism and Related Disorders* 126 (2024): 106986.

47. Hassan YM., *et al*. "Integrating artificial intelligence with nanodiagnostics for early detection and precision management of neurodegenerative diseases". *Journal of Nanobiotechnology* 23.1 (2025): 668.

48. Dipankar P., *et al*. "Artificial intelligence based advancements in nanomedicine for brain disorder management: an updated narrative review". *Frontiers in Medicine (Lausanne)* 12 (2025): 1599340.

49. Tabashum T., *et al*. "Machine learning models for Parkinson disease: systematic review". *JMIR Medical Informatics* 12 (2024): e50117.

50. Alves B., *et al*. "Stakeholder perspectives on trustworthy AI for Parkinson disease management using a cocreation approach: qualitative exploratory study". *Journal of Medical Internet Research* 27 (2025): e73710.

51. Lafi Z., *et al*. "Carbon-based nanotechnology for Parkinson's disease: diagnostic and therapeutic innovations". *Nanomedicine (London)* 20.16 (2025): 2023-2041.

52. Berman SE and Siderowf AD. "Current status of α-synuclein biomarkers and the need for α-synuclein PET tracers". *Cells* 14.16 (2025): 1272.

53. Yadav VK., *et al*. "Recent advances in nanotechnology for Parkinson's disease: diagnosis, treatment, and future perspectives". *Frontiers in Medicine (Lausanne)* 12 (2025): 1535682.

54. Jiang P., *et al*. "Biosensors for early detection of Parkinson's disease: principles, applications, and future prospects". *Biosensors (Basel)* 15.5 (2025): 280.

55. Tolosa E., *et al*. "Challenges in the diagnosis of Parkinson's disease". *Lancet Neurology* 20.5 (2021): 385-397.

Volume 17 Issue 12 December 2025